array:24 [
  "pii" => "S2666275222003071"
  "issn" => "26662752"
  "doi" => "10.1016/j.abdp.2022.12.018"
  "estado" => "S300"
  "fechaPublicacion" => "2023-03-01"
  "aid" => "686"
  "copyright" => "Sociedade Brasileira de Dermatologia"
  "copyrightAnyo" => "2022"
  "documento" => "simple-article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by/4.0/"
  "subdocumento" => "crp"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:19 [
      "pii" => "S0365059622002938"
      "issn" => "03650596"
      "doi" => "10.1016/j.abd.2022.06.003"
      "estado" => "S300"
      "fechaPublicacion" => "2023-03-01"
      "aid" => "686"
      "copyright" => "Sociedade Brasileira de Dermatologia"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by/4.0/"
      "subdocumento" => "crp"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:9 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Letter - Research</span>"
        "titulo" => "Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria&#58; a single-center experience"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "240"
            "paginaFinal" => "242"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "El&#231;in Akda&#351;, Esra Ad&#305;&#351;en, Murat Orhan &#214;zta&#351;, Ahmet Burhan Aksakal, Nilsel &#304;lter, Ayla G&#252;lekon"
            "autores" => array:6 [
              0 => array:2 [
                "nombre" => "El&#231;in"
                "apellidos" => "Akda&#351;"
              ]
              1 => array:2 [
                "nombre" => "Esra"
                "apellidos" => "Ad&#305;&#351;en"
              ]
              2 => array:2 [
                "nombre" => "Murat Orhan"
                "apellidos" => "&#214;zta&#351;"
              ]
              3 => array:2 [
                "nombre" => "Ahmet Burhan"
                "apellidos" => "Aksakal"
              ]
              4 => array:2 [
                "nombre" => "Nilsel"
                "apellidos" => "&#304;lter"
              ]
              5 => array:2 [
                "nombre" => "Ayla"
                "apellidos" => "G&#252;lekon"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "pt" => array:9 [
          "pii" => "S2666275222003071"
          "doi" => "10.1016/j.abdp.2022.12.018"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "pt"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222003071?idApp=UINPBA00008Z"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059622002938?idApp=UINPBA00008Z"
      "url" => "/03650596/0000009800000002/v1_202302171515/S0365059622002938/v1_202302171515/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2666275222003009"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2022.12.011"
    "estado" => "S300"
    "fechaPublicacion" => "2023-03-01"
    "aid" => "681"
    "copyright" => "Sociedade Brasileira de Dermatologia"
    "documento" => "simple-article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "crp"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Carta &#8208; Caso Cl&#237;nico</span>"
      "titulo" => "Caso de carcinoma basocelular localizado na cicatriz umbilical"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "243"
          "paginaFinal" => "244"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1111
              "Ancho" => 3341
              "Tamanyo" => 410046
            ]
          ]
          "descripcion" => array:1 [
            "pt" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Carcinoma basocelular na cicatriz umbilical apresentando&#8208;se clinicamente como les&#227;o &#250;nica&#44; pigmentada de cor escura&#44; medindo 15<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>7<span class="elsevierStyleHsp" style=""></span>mm&#44; com leve descama&#231;&#227;o&#46; &#40;B&#41; O carcinoma basocelular na cicatriz umbilical mostrou grandes ninhos ovais azul&#8208;acinzentados sem rede pigmentada &#224; dermatoscopia&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Maki Takada, Tatsuhiko Mori, Yuka Hanami, Toshiyuki Yamamoto"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Maki"
              "apellidos" => "Takada"
            ]
            1 => array:2 [
              "nombre" => "Tatsuhiko"
              "apellidos" => "Mori"
            ]
            2 => array:2 [
              "nombre" => "Yuka"
              "apellidos" => "Hanami"
            ]
            3 => array:2 [
              "nombre" => "Toshiyuki"
              "apellidos" => "Yamamoto"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0365059622002884"
        "doi" => "10.1016/j.abd.2021.05.023"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059622002884?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222003009?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009800000002/v1_202302281436/S2666275222003009/v1_202302281436/pt/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2666275222003083"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2022.12.019"
    "estado" => "S300"
    "fechaPublicacion" => "2023-03-01"
    "aid" => "687"
    "copyright" => "Sociedade Brasileira de Dermatologia"
    "documento" => "simple-article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "crp"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Cartas &#8208; Investiga&#231;&#227;o</span>"
      "titulo" => "Preval&#234;ncia do polimorfismo do gene filagrina &#40;&#233;xon&#8208;3&#41; em pacientes com dermatite at&#243;pica em popula&#231;&#227;o brasileira multirracial"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "236"
          "paginaFinal" => "239"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1629
              "Ancho" => 3341
              "Tamanyo" => 251502
            ]
          ]
          "descripcion" => array:1 [
            "pt" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Gene <span class="elsevierStyleItalic">FLG</span> incluindo distribui&#231;&#227;o dos &#233;xons&#44; tamanho dos &#233;xons&#44; &#237;ntrons&#44; indica&#231;&#227;o de regi&#227;o de codifica&#231;&#227;o da profilagrina&#44; posi&#231;&#227;o dos <span class="elsevierStyleItalic">primers</span> e eletroferogramas das tr&#234;s mais frequentes variantes patog&#234;nicas encontradas em nossa amostra&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Cristina Marta Maria Laczynski, Carlos D&#8217;Apparecida Santos Machado Filho, H&#233;lio Amante Miot, Denise Maria Christofolini, Itatiana Ferreira Rodart, Paulo Ricardo Criado"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "Cristina Marta Maria"
              "apellidos" => "Laczynski"
            ]
            1 => array:2 [
              "nombre" => "Carlos D&#8217;Apparecida Santos"
              "apellidos" => "Machado Filho"
            ]
            2 => array:2 [
              "nombre" => "H&#233;lio Amante"
              "apellidos" => "Miot"
            ]
            3 => array:2 [
              "nombre" => "Denise Maria"
              "apellidos" => "Christofolini"
            ]
            4 => array:2 [
              "nombre" => "Itatiana Ferreira"
              "apellidos" => "Rodart"
            ]
            5 => array:2 [
              "nombre" => "Paulo Ricardo"
              "apellidos" => "Criado"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S036505962200294X"
        "doi" => "10.1016/j.abd.2022.04.005"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S036505962200294X?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222003083?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009800000002/v1_202302281436/S2666275222003083/v1_202302281436/pt/main.assets"
  ]
  "pt" => array:16 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Cartas &#8208; Investiga&#231;&#227;o</span>"
    "titulo" => "Pr&#225;tica cl&#237;nica com omalizumabe em 134 pacientes com urtic&#225;ria cr&#244;nica espont&#226;nea refrat&#225;ria&#58; experi&#234;ncia de centro &#250;nico"
    "tieneTextoCompleto" => true
    "saludo" => "<span class="elsevierStyleItalic">Prezado Editor</span>&#44;"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "240"
        "paginaFinal" => "242"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "El&#231;in Akda&#351;, Esra Adi&#351;en, Murat Orhan &#214;zta&#351;, Ahmet Burhan Aksakal, Nilsel &#304;lter, Ayla G&#252;lekon"
        "autores" => array:6 [
          0 => array:4 [
            "nombre" => "El&#231;in"
            "apellidos" => "Akda&#351;"
            "email" => array:1 [
              0 => "mdelcinakdas@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:2 [
            "nombre" => "Esra"
            "apellidos" => "Adi&#351;en"
          ]
          2 => array:2 [
            "nombre" => "Murat Orhan"
            "apellidos" => "&#214;zta&#351;"
          ]
          3 => array:2 [
            "nombre" => "Ahmet Burhan"
            "apellidos" => "Aksakal"
          ]
          4 => array:2 [
            "nombre" => "Nilsel"
            "apellidos" => "&#304;lter"
          ]
          5 => array:2 [
            "nombre" => "Ayla"
            "apellidos" => "G&#252;lekon"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Departamento de Dermatologia&#44; Faculdade de Medicina&#44; Gazi Medical University&#44; Ankara&#44; Turquia"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspond&#234;ncia&#46;"
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">A urtic&#225;ria cr&#244;nica espont&#226;nea &#40;UCE&#41; &#233; uma doen&#231;a de alto impacto em termos de custos para o sistema de sa&#250;de&#44; bem como redu&#231;&#227;o do desempenho no trabalho e na vida social e grave deteriora&#231;&#227;o da qualidade de vida&#46; Os anti&#8208;histam&#237;nicos de segunda gera&#231;&#227;o &#40;AHsg&#41; s&#227;o utilizados nas primeiras etapas do tratamento da UCE por serem acess&#237;veis e seguros&#44; mas cerca de metade dos pacientes &#233; resistente aos anti&#8208;histam&#237;nicos&#46;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> O omalizumabe&#44; anticorpo monoclonal anti&#8208;IgE&#44; &#233; tratamento caro mas promissor em pacientes com UCE resistente&#44; em raz&#227;o de sua efic&#225;cia e seguran&#231;a no uso em longo prazo&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> A dose aprovada de omalizumabe em UCE resistente &#233; de 300<span class="elsevierStyleHsp" style=""></span>mg a cada quatro semanas&#46; Recente diretriz internacional recomenda ajustar a dose e o intervalo de acordo com o n&#237;vel de controle da urtic&#225;ria&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Foram avaliados os resultados do tratamento em longo prazo em uma grande coorte de pacientes com UCE resistente que iniciaram o tratamento com omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#46; Os dados foram obtidos dos prontu&#225;rios m&#233;dicos&#46; Os pacientes que receberam pelo menos tr&#234;s doses de omalizumabe entre outubro de 2014 e janeiro de 2021 foram inclu&#237;dos&#46; O presente estudo foi aprovado pelo Comit&#234; de &#201;tica Local da Faculdade de Medicina&#44; de acordo com a Declara&#231;&#227;o de Helsinque&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Neste estudo&#44; o controle da UCE foi ajustado de acordo com o grau de redu&#231;&#227;o dos sintomas relatados pelo paciente e registrados pela avalia&#231;&#227;o m&#233;dica&#58; redu&#231;&#227;o &#8805; 90&#37;&#44; bem controlado&#59; redu&#231;&#227;o de 30&#37; a 89&#37;&#44; moderadamente controlado&#59; &#60;<span class="elsevierStyleHsp" style=""></span>30&#37; de redu&#231;&#227;o&#44; mal controlado&#59; livre de prurido e p&#225;pulas&#44; remiss&#227;o completa&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Foram inclu&#237;dos 134 pacientes&#59; 86 mulheres &#40;64&#44;2&#37;&#41; e 48 homens &#40;35&#44;8&#37;&#41; com idade entre 19 e 71 anos &#40;m&#233;dia&#44; 42&#44;4<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>13&#44;1 anos&#41;&#46; A dura&#231;&#227;o mediana dos sintomas de urtic&#225;ria antes do omalizumabe foi de 17&#44;5 meses &#40;1 a 425 meses&#59; <a class="elsevierStyleCrossRef" href="#tbl0005">tabela 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">No total&#44; 113 &#40;84&#44;3&#37;&#41; pacientes obtiveram remiss&#227;o completa ou sintomas de urtic&#225;ria bem controlados&#44; 17 &#40;12&#44;7&#37;&#41; tiveram controle moderado e quatro &#40;3&#37;&#41; apresentaram sintomas mal controlados&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">O n&#250;mero de tratamentos continuados com omalizumabe na dose de 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas foi &#8804; 6&#44; 7&#8208;15 e &#8805; 16 doses para 56&#47;134 &#40;42&#37;&#41;&#44; 55&#47;134 &#40;41&#37;&#41; e 23&#47;134 &#40;17&#37;&#41; pacientes&#44; respectivamente &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabela 2</a>&#41;&#46; No total&#44; a redu&#231;&#227;o da dose ou o prolongamento do intervalo foi tolerado por 53&#47;134 pacientes &#40;39&#44;5&#37;&#41;&#44; enquanto a dose aumentou em 7&#47;134 pacientes &#40;0&#44;05&#37;&#41;&#46; Vale ressaltar que foram observadas diferen&#231;as estatisticamente significativas entre o &#237;ndice de massa corporal &#40;IMC&#41; dos pacientes que toleraram a redu&#231;&#227;o da dose para 150<span class="elsevierStyleHsp" style=""></span>mg &#40;24&#47;134&#41;&#44; os que continuaram com 300<span class="elsevierStyleHsp" style=""></span>mg &#40;98&#47;134&#41; e os que aumentaram a dose para 450&#8208;600<span class="elsevierStyleHsp" style=""></span>mg &#40;7&#47;134&#59; mediana&#44; kg&#47;m<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a>&#44; 23&#44; 27&#44;4 e 29&#44; respectivamente&#59; teste de Kruskal&#8208;Wallis&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;047&#41;&#46; Al&#233;m disso&#44; os pacientes que toleraram redu&#231;&#227;o para 150<span class="elsevierStyleHsp" style=""></span>mg tinham peso corporal menor estatisticamente significante do que aqueles que continuaram com 300<span class="elsevierStyleHsp" style=""></span>mg e os que aumentaram para 450&#8208;600<span class="elsevierStyleHsp" style=""></span>mg &#40;mediana&#44; kg&#44; 63&#44; 75 e 75&#44; respectivamente&#59; teste de Kruskal&#8208;Wallis&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;040&#41;&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">Uma raz&#227;o de 71&#47;134 pacientes &#40;53&#37;&#41; descontinuou omalizumabe ao final do per&#237;odo de seguimento&#44; dos quais 65 alcan&#231;aram bom controle da urtic&#225;ria ou remiss&#227;o completa e seis em decorr&#234;ncia da falta de resposta ao medicamento&#46; Os pacientes que descontinuaram o tratamento em cada um dos tr&#234;s grupos&#44; independentemente do n&#250;mero de tratamentos com omalizumabe com 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#44; voltaram a ser tratados com omalizumabe ap&#243;s a mesma dura&#231;&#227;o &#40;mediana&#44; cinco meses&#41; por recorr&#234;ncia dos sintomas &#40;teste de Kruskal&#8208;Wallis&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;93&#41;&#46; Os pacientes tratados novamente responderam ao omalizumabe de modo semelhante &#224; sua resposta inicial&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">&#201; interessante notar que a dura&#231;&#227;o dos sintomas de urtic&#225;ria antes do omalizumabe foi fraca&#44; mas positivamente correlacionada com a do omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas alcan&#231;ada pelos pacientes &#40;correla&#231;&#227;o de classifica&#231;&#227;o de Spearman&#44; r<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;231&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;01&#41;&#46; Al&#233;m disso&#44; pacientes com hist&#243;rico de terapia imunossupressora receberam omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas a mais do que aqueles sem hist&#243;rico &#40;mediana de dez <span class="elsevierStyleItalic">vs</span>&#46; seis doses&#44; teste U de Mann&#8208;Whitney&#59; p &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;001&#41;&#46; N&#227;o houve rela&#231;&#227;o entre angioedema concomitante ou urtic&#225;ria induzida e dura&#231;&#227;o do tratamento com omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">N&#227;o foram observados efeitos colaterais graves&#44; mas sim efeitos colaterais leves&#44; que se resolveram espontaneamente em poucos dias&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">Este estudo observacional de pr&#225;tica cl&#237;nica confirmou que o omalizumabe &#233; agente seguro e eficaz em pacientes com UCE resistente &#224; AHsg&#46;<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">4&#44;5</span></a> Os resultados do presente estudo revelaram que um subconjunto de pacientes com UCE resistente que iniciaram tratamento com omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas obteve bons resultados &#8211; sintomas de urtic&#225;ria controlados em curto per&#237;odo de tempo e dura&#231;&#227;o geral do tratamento menor nesses pacientes&#46; Entretanto&#44; em pacientes que receberam omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas por mais de seis doses&#44; a dura&#231;&#227;o do tratamento pode exceder um a tr&#234;s anos&#46; Foi demonstrado que sintomas de urtic&#225;ria de longa dura&#231;&#227;o antes do omalizumabe e hist&#243;ria de terapia imunossupressora sist&#234;mica prolongam a dura&#231;&#227;o do tratamento com omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#46; Da mesma maneira&#44; alguns autores propuseram que sintomas de UCE de longa dura&#231;&#227;o antes da administra&#231;&#227;o de omalizumabe e hist&#243;ria de terapia imunossupressora sist&#234;mica est&#227;o associados a resultados desfavor&#225;veis do tratamento&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">6&#8211;8</span></a> Portanto&#44; a adi&#231;&#227;o imediata de omalizumabe no curso inicial da UCE resistente &#224; AHsg pode encurtar a dura&#231;&#227;o total da terapia com omalizumabe reduzindo o risco de dura&#231;&#227;o prolongada da atividade da urtic&#225;ria&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">Curiosamente&#44; vale ressaltar que&#44; apesar de estudos controlados randomizados terem relatado que 300<span class="elsevierStyleHsp" style=""></span>mg de omalizumabe por m&#234;s era a dose mais eficaz&#44; independentemente do peso do paciente&#44;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> o presente estudo mostrou que pacientes com baixo peso corporal e IMC mantiveram o controle sintom&#225;tico com a dose de 150<span class="elsevierStyleHsp" style=""></span>mg&#46; Semelhante aos resultados do presente estudo&#44; alguns autores tamb&#233;m associaram o uso de doses mais baixas&#44; que geralmente eram determinadas pelo peso corporal dos pacientes&#46;<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">9&#44;10</span></a> Esses achados sugerem que o IMC pode ser preditor valioso para o ajuste da dose de omalizumabe&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">Al&#233;m disso&#44; a recorr&#234;ncia dos sintomas em uma mediana de cinco meses ap&#243;s a descontinua&#231;&#227;o do tratamento&#44; independentemente do n&#250;mero de doses de omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#44; sugere que permanecer na dose inicial por muito tempo n&#227;o contribui para a remiss&#227;o&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">A esse respeito&#44; os autores sugerem que&#44; uma vez que os sintomas estejam bem controlados em pacientes com UCE come&#231;ando com a dose de omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#44; a redu&#231;&#227;o da dose ou o prolongamento gradual do intervalo podem ser tentados&#46; Essa estrat&#233;gia pode proporcionar controle precoce da remiss&#227;o espont&#226;nea&#44; com a possibilidade de prolongamento do tratamento em pacientes que dele necessitem&#44; al&#233;m de boa rela&#231;&#227;o custo&#8208;efetividade&#46; Al&#233;m disso&#44; o controle sintom&#225;tico em pacientes com UCE refrat&#225;ria com baixo peso e&#47;ou IMC pode ser alcan&#231;ado com 150<span class="elsevierStyleHsp" style=""></span>mg&#44; o que pode facilitar o acesso ao omalizumabe&#44; principalmente em pa&#237;ses subdesenvolvidos ou em desenvolvimento&#44; onde a aquisi&#231;&#227;o do medicamento biol&#243;gico &#233; dif&#237;cil&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Suporte financeiro</span><p id="par0070" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Contribui&#231;&#227;o dos autores</span><p id="par0075" class="elsevierStylePara elsevierViewall">El&#231;in Akda&#351;&#58; Obten&#231;&#227;o&#44; an&#225;lise e interpreta&#231;&#227;o dos dados&#59; revis&#227;o cr&#237;tica da literatura&#59; elabora&#231;&#227;o e reda&#231;&#227;o do manuscrito&#59; concep&#231;&#227;o e planejamento do estudo&#44; an&#225;lise estat&#237;stica&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">Esra Ad&#305;&#351;en&#58; Elabora&#231;&#227;o e reda&#231;&#227;o do manuscrito&#59; aprova&#231;&#227;o da vers&#227;o final do manuscrito&#59; concep&#231;&#227;o e planejamento do estudo&#59; revis&#227;o cr&#237;tica do manuscrito&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">Murat Orhan &#214;zta&#351;&#58; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#59; revis&#227;o cr&#237;tica do manuscrito&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">Ahmet Burhan Aksakal&#58; Revis&#227;o cr&#237;tica do manuscrito&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">Nilsel &#304;lter&#58; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#59; revis&#227;o cr&#237;tica do manuscrito&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">Ayla G&#252;lekon&#58; Revis&#227;o cr&#237;tica do manuscrito&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">Todos os autores aprovaram a submiss&#227;o desse manuscrito&#46; Os resultados n&#227;o foram publicados anteriormente e n&#227;o est&#227;o sendo considerados para publica&#231;&#227;o em nenhum outro peri&#243;dico&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Conflito de interesses</span><p id="par0110" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:4 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Suporte financeiro"
        ]
        1 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Contribui&#231;&#227;o dos autores"
        ]
        2 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Conflito de interesses"
        ]
        3 => array:1 [
          "titulo" => "Refer&#234;ncias"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-01-21"
    "fechaAceptado" => "2022-06-11"
    "NotaPie" => array:2 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Como citar este artigo&#58; Akda&#351; E&#44; Adi&#351;en E&#44; &#214;zta&#351; MO&#44; Aksakal AB&#44; &#304;lter N&#44; G&#252;lekon A&#46; Real&#8208;life clinical practice with omalizumab in&#160;134&#160;patients with refractory chronic spontaneous urticaria&#58; a single&#8208;center experience&#46; An Bras Dermatol&#46; 2023&#59;98&#58;244&#8211;6&#46;</p>"
      ]
      1 => array:2 [
        "etiqueta" => "&#9734;&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Trabalho realizado na Gazi Medical University&#44; Ankara&#44; Turquia&#46;</p>"
      ]
    ]
    "multimedia" => array:2 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabela 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">UCE&#44; urtic&#225;ria cr&#244;nica espont&#226;nea&#59; UCI&#44; urtic&#225;ria cr&#244;nica induzida&#59; DP&#44; desvio padr&#227;o&#59; OMA&#44; omalizumabe&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pacientes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Total &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>134&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Diagn&#243;stico&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UEC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">107 &#40;80&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UEC<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>UCI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27 &#40;20&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Idade&#44; m&#233;dia</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">&#177;</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">DP</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42&#44;4<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>13&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Sexo&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Feminino&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">86 &#40;64&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Masculino&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48 &#40;35&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Angioedema&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">71 &#40;53&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">M&#233;dia da idade ao in&#237;cio</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">&#177;</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">DP</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37&#44;3<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>13&#44;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dura&#231;&#227;o dos sintomas de urtic&#225;ria antes do OMA&#44; meses&#44; mediana &#40;intervalo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17&#44;5 &#40;1&#8208;425&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Medicamentos anteriores para UEC&#44; exceto anti&#8208;histam&#237;nico&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Corticosteroides sist&#234;micos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">70 &#40;52&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Ciclosporina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;8&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Doxepina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;8&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas basais de pacientes com urtic&#225;ria cr&#244;nica espont&#226;nea refrat&#225;ria inclu&#237;dos no estudo</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabela 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">UCE&#44; urtic&#225;ria cr&#244;nica espont&#226;nea&#59; UCI&#44; urtic&#225;ria cr&#244;nica induzida&#59; DP&#44; desvio padr&#227;o&#59; OMA&#44; omalizumabe&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">N&#250;mero de doses continuadas com OMA 300&#160;mg&#47;quatro semanas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Primeiro grupo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Segundo grupo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Terceiro grupo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">p&#8208;valor&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#8804; 6 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">7&#8211;15 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#8805; 16 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">56 &#40;42&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">55 &#40;41&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23 &#40;17&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dura&#231;&#227;o da urtic&#225;ria antes do OMA&#44; meses&#44; mediana &#40;intervalo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&#44;5 &#40;3&#44;2&#8208;43&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;6&#8208;62&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48 &#40;8&#8208;120&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">N&#250;mero total de doses do OMA&#44; n&#44; mediana &#40;intervalo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;3&#8208;28&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;7&#8208;36&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27 &#40;16&#8208;78&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;<span class="elsevierStyleHsp" style=""></span>0&#44;001<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dura&#231;&#227;o total do tratamento com OMA&#44; meses&#44; mediana &#40;intervalo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#44;5 &#40;3&#8208;44&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;7&#8208;50&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">32&#44;5 &#40;16&#8208;72&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;<span class="elsevierStyleHsp" style=""></span>0&#44;001<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Mudan&#231;as de doses e intervalos&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Sem altera&#231;&#227;o &#40;300 mg&#47;quatro semanas&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25 &#40;18&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">35 &#40;26&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14 &#40;10&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Intervalos estendidos &#40;300 mg&#47;cinco semanas &#60;<span class="elsevierStyleHsp" style=""></span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">19 &#40;14&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;1&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Dose reduzida &#40;150 mg&#47;quatro semanas&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;8&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;3&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Dose aumentada &#40;450&#8208;600 mg&#47;quatro semanas&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;0&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;1&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes que continuaram com o OMA&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">22 &#40;16&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30 &#40;22&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;8&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes que descontinuaram o OMA&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">34 &#40;22&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25 &#40;18&#44;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12 &#40;8&#44;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Doen&#231;a recorrente&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;6&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14 &#40;10&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;3&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Tempo para recorr&#234;ncia&#44; meses&#44; mediana &#40;intervalo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;3&#44;5&#8208;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;3&#8208;11&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;4&#8208;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">p&#8208;valor significativo ao n&#237;vel de p &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;05&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas cl&#237;nicas do omalizumabe em 134 pacientes com urtic&#225;ria cr&#244;nica espont&#226;nea refrat&#225;ria</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Refer&#234;ncias"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:10 [
            0 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Unmet clinical needs in chronic spontaneous urticaria&#46; A GA<span class="elsevierStyleSup">2</span>LEN task force report"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Maurer"
                            1 => "K&#46; Weller"
                            2 => "C&#46; Bindslev-Jensen"
                            3 => "A&#46; Gim&#233;nez-Arnau"
                            4 => "P&#46;J&#46; Bousquet"
                            5 => "J&#46; Bousquet"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1398-9995.2010.02496.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy&#46;"
                        "fecha" => "2011"
                        "volumen" => "66"
                        "paginaInicial" => "317"
                        "paginaFinal" => "330"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21083565"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Update on omalizumab for urticaria&#58; what&#39;s new in the literature from mechanisms to clinic"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;E&#46; Larenas-Linnemann"
                            1 => "C&#46;A&#46; Parisi"
                            2 => "C&#46; Ritchie"
                            3 => "R&#46; Cardona-Villa"
                            4 => "I&#46; Cherrez-Ojeda"
                            5 => "A&#46; Cherrez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11882-018-0787-5"
                      "Revista" => array:5 [
                        "tituloSerie" => "Curr Allergy Asthma Rep&#46;"
                        "fecha" => "2018"
                        "volumen" => "18"
                        "paginaInicial" => "33"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29744661"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The international EAACI&#47;GA<span class="elsevierStyleSup">2</span>LEN&#47;EuroGuiDerm&#47;APAAACI guideline for the definition&#44; classification&#44; diagnosis&#44; and management of urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Zuberbier"
                            1 => "A&#46;H&#46;A&#46; Latiff"
                            2 => "M&#46; Abuzakouk"
                            3 => "S&#46; Aquilina"
                            4 => "R&#46; Asero"
                            5 => "D&#46; Baker"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/all.15090"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy&#46;"
                        "fecha" => "2022"
                        "volumen" => "77"
                        "paginaInicial" => "734"
                        "paginaFinal" => "766"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34536239"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab for the treatment of chronic spontaneous urticaria&#58; a meta&#8208;analysis of randomized clinical trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Z&#46;-T&#46; Zhao"
                            1 => "C&#46;-M&#46; Ji"
                            2 => "W&#46;-J&#46; Yu"
                            3 => "L&#46; Meng"
                            4 => "T&#46; Hawro"
                            5 => "J&#46;F&#46; Wei"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaci.2015.12.1342"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol"
                        "fecha" => "2016"
                        "volumen" => "137"
                        "paginaInicial" => "1742"
                        "paginaFinal" => "1750"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27040372"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic&#47;spontaneous urticaria&#58; a systematic review of &#8216;real&#8208;world&#8217;evidence"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;A&#46; Bernstein"
                            1 => "A&#46; Kavati"
                            2 => "M&#46;D&#46; Tharp"
                            3 => "B&#46; Ortiz"
                            4 => "K&#46; MacDonald"
                            5 => "K&#46; Denhaerynck"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Expert Opin Biol Ther&#46;"
                        "fecha" => "2018"
                        "volumen" => "18"
                        "paginaInicial" => "425"
                        "paginaFinal" => "448"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria&#58; evaluation of 154 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46;N&#46; Ghazanfar"
                            1 => "C&#46; Sand"
                            2 => "S&#46;F&#46; Thomsen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "The British journal of dermatology&#46;"
                        "fecha" => "2016"
                        "volumen" => "175"
                        "paginaInicial" => "404"
                        "paginaFinal" => "406"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab for severe chronic spontaneous urticaria&#58; real&#8208;life experiences of 280 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Z&#46; Vadasz"
                            1 => "Y&#46; Tal"
                            2 => "M&#46; Rotem"
                            3 => "V&#46; Shichter-Confino"
                            4 => "K&#46; Mahlab-Guri"
                            5 => "Y&#46; Graif"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2017.08.035"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2017"
                        "volumen" => "5"
                        "paginaInicial" => "1743"
                        "paginaFinal" => "1745"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28988786"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab chronic spontaneous urticaria&#58; efficacy&#44; safety&#44; predictors of treatment outcome&#44; and time to response"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Nettis"
                            1 => "L&#46; Cegolon"
                            2 => "E&#46; Di Leo"
                            3 => "F&#46;L&#46; Rizzini"
                            4 => "A&#46; Detoraki"
                            5 => "G&#46;W&#46; Canonica"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anai.2018.06.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Allergy Asthma Immunol&#46;"
                        "fecha" => "2018"
                        "volumen" => "121"
                        "paginaInicial" => "474"
                        "paginaFinal" => "478"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29949781"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab is an effective and rapidly acting therapy in difficult&#8208;to&#8208;treat chronic urticaria&#58; a retrospective clinical analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46; Metz"
                            1 => "T&#46; Ohanyan"
                            2 => "M&#46;K&#46; Church"
                            3 => "M&#46; Maurer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Dermatol Sci&#46;"
                        "fecha" => "2014"
                        "volumen" => "73"
                        "paginaInicial" => "57"
                        "paginaFinal" => "62"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "K&#46; Kulthanan"
                            1 => "P&#46; Tuchinda"
                            2 => "L&#46; Chularojanamontri"
                            3 => "C&#46; Likitwattananurak"
                            4 => "C&#46; Ungaksornpairote"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/09546634.2016.1200710"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatolog Treat&#46;"
                        "fecha" => "2017"
                        "volumen" => "28"
                        "paginaInicial" => "160"
                        "paginaFinal" => "165"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27388043"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "pt"
  "url" => "/26662752/0000009800000002/v1_202302281436/S2666275222003071/v1_202302281436/pt/main.assets"
  "Apartado" => array:4 [
    "identificador" => "95147"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Cartas - Investiga&#231;&#227;o"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/26662752/0000009800000002/v1_202302281436/S2666275222003071/v1_202302281436/pt/main.pdf?idApp=UINPBA00008Z&text.app=https://clinics.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222003071?idApp=UINPBA00008Z"
]
Compartilhar
Informação da revista

Estatísticas

Siga este link para acessar o texto completo do artigo

Cartas ‐ Investigação
Prática clínica com omalizumabe em 134 pacientes com urticária crônica espontânea refratária: experiência de centro único
Elçin Akdaş
Autor para correspondência
mdelcinakdas@gmail.com

Autor para correspondência.
, Esra Adişen, Murat Orhan Öztaş, Ahmet Burhan Aksakal, Nilsel İlter, Ayla Gülekon
Departamento de Dermatologia, Faculdade de Medicina, Gazi Medical University, Ankara, Turquia
Lido
4335
Vezes
que se leu este artigo
1451
Total PDF
2884
Total HTML
Compartilhar estatísticas
 array:24 [
  "pii" => "S2666275222003071"
  "issn" => "26662752"
  "doi" => "10.1016/j.abdp.2022.12.018"
  "estado" => "S300"
  "fechaPublicacion" => "2023-03-01"
  "aid" => "686"
  "copyright" => "Sociedade Brasileira de Dermatologia"
  "copyrightAnyo" => "2022"
  "documento" => "simple-article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by/4.0/"
  "subdocumento" => "crp"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:19 [
      "pii" => "S0365059622002938"
      "issn" => "03650596"
      "doi" => "10.1016/j.abd.2022.06.003"
      "estado" => "S300"
      "fechaPublicacion" => "2023-03-01"
      "aid" => "686"
      "copyright" => "Sociedade Brasileira de Dermatologia"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by/4.0/"
      "subdocumento" => "crp"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:9 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Letter - Research</span>"
        "titulo" => "Real-life clinical practice with omalizumab in 134 patients with refractory chronic spontaneous urticaria&#58; a single-center experience"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "240"
            "paginaFinal" => "242"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "El&#231;in Akda&#351;, Esra Ad&#305;&#351;en, Murat Orhan &#214;zta&#351;, Ahmet Burhan Aksakal, Nilsel &#304;lter, Ayla G&#252;lekon"
            "autores" => array:6 [
              0 => array:2 [
                "nombre" => "El&#231;in"
                "apellidos" => "Akda&#351;"
              ]
              1 => array:2 [
                "nombre" => "Esra"
                "apellidos" => "Ad&#305;&#351;en"
              ]
              2 => array:2 [
                "nombre" => "Murat Orhan"
                "apellidos" => "&#214;zta&#351;"
              ]
              3 => array:2 [
                "nombre" => "Ahmet Burhan"
                "apellidos" => "Aksakal"
              ]
              4 => array:2 [
                "nombre" => "Nilsel"
                "apellidos" => "&#304;lter"
              ]
              5 => array:2 [
                "nombre" => "Ayla"
                "apellidos" => "G&#252;lekon"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "pt" => array:9 [
          "pii" => "S2666275222003071"
          "doi" => "10.1016/j.abdp.2022.12.018"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "pt"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222003071?idApp=UINPBA00008Z"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059622002938?idApp=UINPBA00008Z"
      "url" => "/03650596/0000009800000002/v1_202302171515/S0365059622002938/v1_202302171515/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S2666275222003009"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2022.12.011"
    "estado" => "S300"
    "fechaPublicacion" => "2023-03-01"
    "aid" => "681"
    "copyright" => "Sociedade Brasileira de Dermatologia"
    "documento" => "simple-article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "crp"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Carta &#8208; Caso Cl&#237;nico</span>"
      "titulo" => "Caso de carcinoma basocelular localizado na cicatriz umbilical"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "243"
          "paginaFinal" => "244"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1111
              "Ancho" => 3341
              "Tamanyo" => 410046
            ]
          ]
          "descripcion" => array:1 [
            "pt" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Carcinoma basocelular na cicatriz umbilical apresentando&#8208;se clinicamente como les&#227;o &#250;nica&#44; pigmentada de cor escura&#44; medindo 15<span class="elsevierStyleHsp" style=""></span>&#215;<span class="elsevierStyleHsp" style=""></span>7<span class="elsevierStyleHsp" style=""></span>mm&#44; com leve descama&#231;&#227;o&#46; &#40;B&#41; O carcinoma basocelular na cicatriz umbilical mostrou grandes ninhos ovais azul&#8208;acinzentados sem rede pigmentada &#224; dermatoscopia&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Maki Takada, Tatsuhiko Mori, Yuka Hanami, Toshiyuki Yamamoto"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Maki"
              "apellidos" => "Takada"
            ]
            1 => array:2 [
              "nombre" => "Tatsuhiko"
              "apellidos" => "Mori"
            ]
            2 => array:2 [
              "nombre" => "Yuka"
              "apellidos" => "Hanami"
            ]
            3 => array:2 [
              "nombre" => "Toshiyuki"
              "apellidos" => "Yamamoto"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0365059622002884"
        "doi" => "10.1016/j.abd.2021.05.023"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059622002884?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222003009?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009800000002/v1_202302281436/S2666275222003009/v1_202302281436/pt/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2666275222003083"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2022.12.019"
    "estado" => "S300"
    "fechaPublicacion" => "2023-03-01"
    "aid" => "687"
    "copyright" => "Sociedade Brasileira de Dermatologia"
    "documento" => "simple-article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "crp"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:10 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Cartas &#8208; Investiga&#231;&#227;o</span>"
      "titulo" => "Preval&#234;ncia do polimorfismo do gene filagrina &#40;&#233;xon&#8208;3&#41; em pacientes com dermatite at&#243;pica em popula&#231;&#227;o brasileira multirracial"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "236"
          "paginaFinal" => "239"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1629
              "Ancho" => 3341
              "Tamanyo" => 251502
            ]
          ]
          "descripcion" => array:1 [
            "pt" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Gene <span class="elsevierStyleItalic">FLG</span> incluindo distribui&#231;&#227;o dos &#233;xons&#44; tamanho dos &#233;xons&#44; &#237;ntrons&#44; indica&#231;&#227;o de regi&#227;o de codifica&#231;&#227;o da profilagrina&#44; posi&#231;&#227;o dos <span class="elsevierStyleItalic">primers</span> e eletroferogramas das tr&#234;s mais frequentes variantes patog&#234;nicas encontradas em nossa amostra&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Cristina Marta Maria Laczynski, Carlos D&#8217;Apparecida Santos Machado Filho, H&#233;lio Amante Miot, Denise Maria Christofolini, Itatiana Ferreira Rodart, Paulo Ricardo Criado"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "Cristina Marta Maria"
              "apellidos" => "Laczynski"
            ]
            1 => array:2 [
              "nombre" => "Carlos D&#8217;Apparecida Santos"
              "apellidos" => "Machado Filho"
            ]
            2 => array:2 [
              "nombre" => "H&#233;lio Amante"
              "apellidos" => "Miot"
            ]
            3 => array:2 [
              "nombre" => "Denise Maria"
              "apellidos" => "Christofolini"
            ]
            4 => array:2 [
              "nombre" => "Itatiana Ferreira"
              "apellidos" => "Rodart"
            ]
            5 => array:2 [
              "nombre" => "Paulo Ricardo"
              "apellidos" => "Criado"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S036505962200294X"
        "doi" => "10.1016/j.abd.2022.04.005"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S036505962200294X?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222003083?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009800000002/v1_202302281436/S2666275222003083/v1_202302281436/pt/main.assets"
  ]
  "pt" => array:16 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Cartas &#8208; Investiga&#231;&#227;o</span>"
    "titulo" => "Pr&#225;tica cl&#237;nica com omalizumabe em 134 pacientes com urtic&#225;ria cr&#244;nica espont&#226;nea refrat&#225;ria&#58; experi&#234;ncia de centro &#250;nico"
    "tieneTextoCompleto" => true
    "saludo" => "<span class="elsevierStyleItalic">Prezado Editor</span>&#44;"
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "240"
        "paginaFinal" => "242"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "El&#231;in Akda&#351;, Esra Adi&#351;en, Murat Orhan &#214;zta&#351;, Ahmet Burhan Aksakal, Nilsel &#304;lter, Ayla G&#252;lekon"
        "autores" => array:6 [
          0 => array:4 [
            "nombre" => "El&#231;in"
            "apellidos" => "Akda&#351;"
            "email" => array:1 [
              0 => "mdelcinakdas@gmail.com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:2 [
            "nombre" => "Esra"
            "apellidos" => "Adi&#351;en"
          ]
          2 => array:2 [
            "nombre" => "Murat Orhan"
            "apellidos" => "&#214;zta&#351;"
          ]
          3 => array:2 [
            "nombre" => "Ahmet Burhan"
            "apellidos" => "Aksakal"
          ]
          4 => array:2 [
            "nombre" => "Nilsel"
            "apellidos" => "&#304;lter"
          ]
          5 => array:2 [
            "nombre" => "Ayla"
            "apellidos" => "G&#252;lekon"
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Departamento de Dermatologia&#44; Faculdade de Medicina&#44; Gazi Medical University&#44; Ankara&#44; Turquia"
            "identificador" => "aff0005"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspond&#234;ncia&#46;"
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">A urtic&#225;ria cr&#244;nica espont&#226;nea &#40;UCE&#41; &#233; uma doen&#231;a de alto impacto em termos de custos para o sistema de sa&#250;de&#44; bem como redu&#231;&#227;o do desempenho no trabalho e na vida social e grave deteriora&#231;&#227;o da qualidade de vida&#46; Os anti&#8208;histam&#237;nicos de segunda gera&#231;&#227;o &#40;AHsg&#41; s&#227;o utilizados nas primeiras etapas do tratamento da UCE por serem acess&#237;veis e seguros&#44; mas cerca de metade dos pacientes &#233; resistente aos anti&#8208;histam&#237;nicos&#46;<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> O omalizumabe&#44; anticorpo monoclonal anti&#8208;IgE&#44; &#233; tratamento caro mas promissor em pacientes com UCE resistente&#44; em raz&#227;o de sua efic&#225;cia e seguran&#231;a no uso em longo prazo&#46;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> A dose aprovada de omalizumabe em UCE resistente &#233; de 300<span class="elsevierStyleHsp" style=""></span>mg a cada quatro semanas&#46; Recente diretriz internacional recomenda ajustar a dose e o intervalo de acordo com o n&#237;vel de controle da urtic&#225;ria&#46;<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Foram avaliados os resultados do tratamento em longo prazo em uma grande coorte de pacientes com UCE resistente que iniciaram o tratamento com omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#46; Os dados foram obtidos dos prontu&#225;rios m&#233;dicos&#46; Os pacientes que receberam pelo menos tr&#234;s doses de omalizumabe entre outubro de 2014 e janeiro de 2021 foram inclu&#237;dos&#46; O presente estudo foi aprovado pelo Comit&#234; de &#201;tica Local da Faculdade de Medicina&#44; de acordo com a Declara&#231;&#227;o de Helsinque&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Neste estudo&#44; o controle da UCE foi ajustado de acordo com o grau de redu&#231;&#227;o dos sintomas relatados pelo paciente e registrados pela avalia&#231;&#227;o m&#233;dica&#58; redu&#231;&#227;o &#8805; 90&#37;&#44; bem controlado&#59; redu&#231;&#227;o de 30&#37; a 89&#37;&#44; moderadamente controlado&#59; &#60;<span class="elsevierStyleHsp" style=""></span>30&#37; de redu&#231;&#227;o&#44; mal controlado&#59; livre de prurido e p&#225;pulas&#44; remiss&#227;o completa&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">Foram inclu&#237;dos 134 pacientes&#59; 86 mulheres &#40;64&#44;2&#37;&#41; e 48 homens &#40;35&#44;8&#37;&#41; com idade entre 19 e 71 anos &#40;m&#233;dia&#44; 42&#44;4<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>13&#44;1 anos&#41;&#46; A dura&#231;&#227;o mediana dos sintomas de urtic&#225;ria antes do omalizumabe foi de 17&#44;5 meses &#40;1 a 425 meses&#59; <a class="elsevierStyleCrossRef" href="#tbl0005">tabela 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">No total&#44; 113 &#40;84&#44;3&#37;&#41; pacientes obtiveram remiss&#227;o completa ou sintomas de urtic&#225;ria bem controlados&#44; 17 &#40;12&#44;7&#37;&#41; tiveram controle moderado e quatro &#40;3&#37;&#41; apresentaram sintomas mal controlados&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">O n&#250;mero de tratamentos continuados com omalizumabe na dose de 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas foi &#8804; 6&#44; 7&#8208;15 e &#8805; 16 doses para 56&#47;134 &#40;42&#37;&#41;&#44; 55&#47;134 &#40;41&#37;&#41; e 23&#47;134 &#40;17&#37;&#41; pacientes&#44; respectivamente &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabela 2</a>&#41;&#46; No total&#44; a redu&#231;&#227;o da dose ou o prolongamento do intervalo foi tolerado por 53&#47;134 pacientes &#40;39&#44;5&#37;&#41;&#44; enquanto a dose aumentou em 7&#47;134 pacientes &#40;0&#44;05&#37;&#41;&#46; Vale ressaltar que foram observadas diferen&#231;as estatisticamente significativas entre o &#237;ndice de massa corporal &#40;IMC&#41; dos pacientes que toleraram a redu&#231;&#227;o da dose para 150<span class="elsevierStyleHsp" style=""></span>mg &#40;24&#47;134&#41;&#44; os que continuaram com 300<span class="elsevierStyleHsp" style=""></span>mg &#40;98&#47;134&#41; e os que aumentaram a dose para 450&#8208;600<span class="elsevierStyleHsp" style=""></span>mg &#40;7&#47;134&#59; mediana&#44; kg&#47;m<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a>&#44; 23&#44; 27&#44;4 e 29&#44; respectivamente&#59; teste de Kruskal&#8208;Wallis&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;047&#41;&#46; Al&#233;m disso&#44; os pacientes que toleraram redu&#231;&#227;o para 150<span class="elsevierStyleHsp" style=""></span>mg tinham peso corporal menor estatisticamente significante do que aqueles que continuaram com 300<span class="elsevierStyleHsp" style=""></span>mg e os que aumentaram para 450&#8208;600<span class="elsevierStyleHsp" style=""></span>mg &#40;mediana&#44; kg&#44; 63&#44; 75 e 75&#44; respectivamente&#59; teste de Kruskal&#8208;Wallis&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;040&#41;&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">Uma raz&#227;o de 71&#47;134 pacientes &#40;53&#37;&#41; descontinuou omalizumabe ao final do per&#237;odo de seguimento&#44; dos quais 65 alcan&#231;aram bom controle da urtic&#225;ria ou remiss&#227;o completa e seis em decorr&#234;ncia da falta de resposta ao medicamento&#46; Os pacientes que descontinuaram o tratamento em cada um dos tr&#234;s grupos&#44; independentemente do n&#250;mero de tratamentos com omalizumabe com 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#44; voltaram a ser tratados com omalizumabe ap&#243;s a mesma dura&#231;&#227;o &#40;mediana&#44; cinco meses&#41; por recorr&#234;ncia dos sintomas &#40;teste de Kruskal&#8208;Wallis&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;93&#41;&#46; Os pacientes tratados novamente responderam ao omalizumabe de modo semelhante &#224; sua resposta inicial&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">&#201; interessante notar que a dura&#231;&#227;o dos sintomas de urtic&#225;ria antes do omalizumabe foi fraca&#44; mas positivamente correlacionada com a do omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas alcan&#231;ada pelos pacientes &#40;correla&#231;&#227;o de classifica&#231;&#227;o de Spearman&#44; r<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;231&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;01&#41;&#46; Al&#233;m disso&#44; pacientes com hist&#243;rico de terapia imunossupressora receberam omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas a mais do que aqueles sem hist&#243;rico &#40;mediana de dez <span class="elsevierStyleItalic">vs</span>&#46; seis doses&#44; teste U de Mann&#8208;Whitney&#59; p &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;001&#41;&#46; N&#227;o houve rela&#231;&#227;o entre angioedema concomitante ou urtic&#225;ria induzida e dura&#231;&#227;o do tratamento com omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">N&#227;o foram observados efeitos colaterais graves&#44; mas sim efeitos colaterais leves&#44; que se resolveram espontaneamente em poucos dias&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">Este estudo observacional de pr&#225;tica cl&#237;nica confirmou que o omalizumabe &#233; agente seguro e eficaz em pacientes com UCE resistente &#224; AHsg&#46;<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">4&#44;5</span></a> Os resultados do presente estudo revelaram que um subconjunto de pacientes com UCE resistente que iniciaram tratamento com omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas obteve bons resultados &#8211; sintomas de urtic&#225;ria controlados em curto per&#237;odo de tempo e dura&#231;&#227;o geral do tratamento menor nesses pacientes&#46; Entretanto&#44; em pacientes que receberam omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas por mais de seis doses&#44; a dura&#231;&#227;o do tratamento pode exceder um a tr&#234;s anos&#46; Foi demonstrado que sintomas de urtic&#225;ria de longa dura&#231;&#227;o antes do omalizumabe e hist&#243;ria de terapia imunossupressora sist&#234;mica prolongam a dura&#231;&#227;o do tratamento com omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#46; Da mesma maneira&#44; alguns autores propuseram que sintomas de UCE de longa dura&#231;&#227;o antes da administra&#231;&#227;o de omalizumabe e hist&#243;ria de terapia imunossupressora sist&#234;mica est&#227;o associados a resultados desfavor&#225;veis do tratamento&#46;<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">6&#8211;8</span></a> Portanto&#44; a adi&#231;&#227;o imediata de omalizumabe no curso inicial da UCE resistente &#224; AHsg pode encurtar a dura&#231;&#227;o total da terapia com omalizumabe reduzindo o risco de dura&#231;&#227;o prolongada da atividade da urtic&#225;ria&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">Curiosamente&#44; vale ressaltar que&#44; apesar de estudos controlados randomizados terem relatado que 300<span class="elsevierStyleHsp" style=""></span>mg de omalizumabe por m&#234;s era a dose mais eficaz&#44; independentemente do peso do paciente&#44;<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> o presente estudo mostrou que pacientes com baixo peso corporal e IMC mantiveram o controle sintom&#225;tico com a dose de 150<span class="elsevierStyleHsp" style=""></span>mg&#46; Semelhante aos resultados do presente estudo&#44; alguns autores tamb&#233;m associaram o uso de doses mais baixas&#44; que geralmente eram determinadas pelo peso corporal dos pacientes&#46;<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">9&#44;10</span></a> Esses achados sugerem que o IMC pode ser preditor valioso para o ajuste da dose de omalizumabe&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">Al&#233;m disso&#44; a recorr&#234;ncia dos sintomas em uma mediana de cinco meses ap&#243;s a descontinua&#231;&#227;o do tratamento&#44; independentemente do n&#250;mero de doses de omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#44; sugere que permanecer na dose inicial por muito tempo n&#227;o contribui para a remiss&#227;o&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">A esse respeito&#44; os autores sugerem que&#44; uma vez que os sintomas estejam bem controlados em pacientes com UCE come&#231;ando com a dose de omalizumabe 300<span class="elsevierStyleHsp" style=""></span>mg&#47;quatro semanas&#44; a redu&#231;&#227;o da dose ou o prolongamento gradual do intervalo podem ser tentados&#46; Essa estrat&#233;gia pode proporcionar controle precoce da remiss&#227;o espont&#226;nea&#44; com a possibilidade de prolongamento do tratamento em pacientes que dele necessitem&#44; al&#233;m de boa rela&#231;&#227;o custo&#8208;efetividade&#46; Al&#233;m disso&#44; o controle sintom&#225;tico em pacientes com UCE refrat&#225;ria com baixo peso e&#47;ou IMC pode ser alcan&#231;ado com 150<span class="elsevierStyleHsp" style=""></span>mg&#44; o que pode facilitar o acesso ao omalizumabe&#44; principalmente em pa&#237;ses subdesenvolvidos ou em desenvolvimento&#44; onde a aquisi&#231;&#227;o do medicamento biol&#243;gico &#233; dif&#237;cil&#46;</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Suporte financeiro</span><p id="par0070" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Contribui&#231;&#227;o dos autores</span><p id="par0075" class="elsevierStylePara elsevierViewall">El&#231;in Akda&#351;&#58; Obten&#231;&#227;o&#44; an&#225;lise e interpreta&#231;&#227;o dos dados&#59; revis&#227;o cr&#237;tica da literatura&#59; elabora&#231;&#227;o e reda&#231;&#227;o do manuscrito&#59; concep&#231;&#227;o e planejamento do estudo&#44; an&#225;lise estat&#237;stica&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">Esra Ad&#305;&#351;en&#58; Elabora&#231;&#227;o e reda&#231;&#227;o do manuscrito&#59; aprova&#231;&#227;o da vers&#227;o final do manuscrito&#59; concep&#231;&#227;o e planejamento do estudo&#59; revis&#227;o cr&#237;tica do manuscrito&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">Murat Orhan &#214;zta&#351;&#58; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#59; revis&#227;o cr&#237;tica do manuscrito&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">Ahmet Burhan Aksakal&#58; Revis&#227;o cr&#237;tica do manuscrito&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">Nilsel &#304;lter&#58; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#59; revis&#227;o cr&#237;tica do manuscrito&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">Ayla G&#252;lekon&#58; Revis&#227;o cr&#237;tica do manuscrito&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">Todos os autores aprovaram a submiss&#227;o desse manuscrito&#46; Os resultados n&#227;o foram publicados anteriormente e n&#227;o est&#227;o sendo considerados para publica&#231;&#227;o em nenhum outro peri&#243;dico&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Conflito de interesses</span><p id="par0110" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:4 [
        0 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Suporte financeiro"
        ]
        1 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Contribui&#231;&#227;o dos autores"
        ]
        2 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Conflito de interesses"
        ]
        3 => array:1 [
          "titulo" => "Refer&#234;ncias"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-01-21"
    "fechaAceptado" => "2022-06-11"
    "NotaPie" => array:2 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Como citar este artigo&#58; Akda&#351; E&#44; Adi&#351;en E&#44; &#214;zta&#351; MO&#44; Aksakal AB&#44; &#304;lter N&#44; G&#252;lekon A&#46; Real&#8208;life clinical practice with omalizumab in&#160;134&#160;patients with refractory chronic spontaneous urticaria&#58; a single&#8208;center experience&#46; An Bras Dermatol&#46; 2023&#59;98&#58;244&#8211;6&#46;</p>"
      ]
      1 => array:2 [
        "etiqueta" => "&#9734;&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Trabalho realizado na Gazi Medical University&#44; Ankara&#44; Turquia&#46;</p>"
      ]
    ]
    "multimedia" => array:2 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabela 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">UCE&#44; urtic&#225;ria cr&#244;nica espont&#226;nea&#59; UCI&#44; urtic&#225;ria cr&#244;nica induzida&#59; DP&#44; desvio padr&#227;o&#59; OMA&#44; omalizumabe&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Pacientes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Total &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>134&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Diagn&#243;stico&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UEC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">107 &#40;80&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UEC<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>UCI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27 &#40;20&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Idade&#44; m&#233;dia</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">&#177;</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">DP</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42&#44;4<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>13&#44;1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Sexo&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Feminino&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">86 &#40;64&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Masculino&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48 &#40;35&#44;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Angioedema&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">71 &#40;53&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">M&#233;dia da idade ao in&#237;cio</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">&#177;</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">DP</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37&#44;3<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>13&#44;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dura&#231;&#227;o dos sintomas de urtic&#225;ria antes do OMA&#44; meses&#44; mediana &#40;intervalo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17&#44;5 &#40;1&#8208;425&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Medicamentos anteriores para UEC&#44; exceto anti&#8208;histam&#237;nico&#44; n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Corticosteroides sist&#234;micos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">70 &#40;52&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Ciclosporina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;8&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Doxepina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;8&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas basais de pacientes com urtic&#225;ria cr&#244;nica espont&#226;nea refrat&#225;ria inclu&#237;dos no estudo</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabela 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">UCE&#44; urtic&#225;ria cr&#244;nica espont&#226;nea&#59; UCI&#44; urtic&#225;ria cr&#244;nica induzida&#59; DP&#44; desvio padr&#227;o&#59; OMA&#44; omalizumabe&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td-with-role" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">N&#250;mero de doses continuadas com OMA 300&#160;mg&#47;quatro semanas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Primeiro grupo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Segundo grupo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">Terceiro grupo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">p&#8208;valor&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#8804; 6 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">7&#8211;15 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&#8805; 16 doses&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">56 &#40;42&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">55 &#40;41&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23 &#40;17&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dura&#231;&#227;o da urtic&#225;ria antes do OMA&#44; meses&#44; mediana &#40;intervalo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10&#44;5 &#40;3&#44;2&#8208;43&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;6&#8208;62&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48 &#40;8&#8208;120&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">N&#250;mero total de doses do OMA&#44; n&#44; mediana &#40;intervalo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;3&#8208;28&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;7&#8208;36&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27 &#40;16&#8208;78&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;<span class="elsevierStyleHsp" style=""></span>0&#44;001<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dura&#231;&#227;o total do tratamento com OMA&#44; meses&#44; mediana &#40;intervalo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#44;5 &#40;3&#8208;44&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;7&#8208;50&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">32&#44;5 &#40;16&#8208;72&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60;<span class="elsevierStyleHsp" style=""></span>0&#44;001<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Mudan&#231;as de doses e intervalos&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Sem altera&#231;&#227;o &#40;300 mg&#47;quatro semanas&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25 &#40;18&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">35 &#40;26&#44;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14 &#40;10&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Intervalos estendidos &#40;300 mg&#47;cinco semanas &#60;<span class="elsevierStyleHsp" style=""></span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">19 &#40;14&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;1&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Dose reduzida &#40;150 mg&#47;quatro semanas&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;8&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;3&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Dose aumentada &#40;450&#8208;600 mg&#47;quatro semanas&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;0&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;1&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes que continuaram com o OMA&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">22 &#40;16&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">30 &#40;22&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;8&#44;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Pacientes que descontinuaram o OMA&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">34 &#40;22&#44;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25 &#40;18&#44;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12 &#40;8&#44;9&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Doen&#231;a recorrente&#44; n &#40;&#37;&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;6&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14 &#40;10&#44;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;3&#44;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Tempo para recorr&#234;ncia&#44; meses&#44; mediana &#40;intervalo&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;3&#44;5&#8208;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;3&#8208;11&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;4&#8208;7&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">p&#8208;valor significativo ao n&#237;vel de p &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;05&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas cl&#237;nicas do omalizumabe em 134 pacientes com urtic&#225;ria cr&#244;nica espont&#226;nea refrat&#225;ria</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Refer&#234;ncias"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:10 [
            0 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Unmet clinical needs in chronic spontaneous urticaria&#46; A GA<span class="elsevierStyleSup">2</span>LEN task force report"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Maurer"
                            1 => "K&#46; Weller"
                            2 => "C&#46; Bindslev-Jensen"
                            3 => "A&#46; Gim&#233;nez-Arnau"
                            4 => "P&#46;J&#46; Bousquet"
                            5 => "J&#46; Bousquet"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1398-9995.2010.02496.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy&#46;"
                        "fecha" => "2011"
                        "volumen" => "66"
                        "paginaInicial" => "317"
                        "paginaFinal" => "330"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21083565"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Update on omalizumab for urticaria&#58; what&#39;s new in the literature from mechanisms to clinic"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;E&#46; Larenas-Linnemann"
                            1 => "C&#46;A&#46; Parisi"
                            2 => "C&#46; Ritchie"
                            3 => "R&#46; Cardona-Villa"
                            4 => "I&#46; Cherrez-Ojeda"
                            5 => "A&#46; Cherrez"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11882-018-0787-5"
                      "Revista" => array:5 [
                        "tituloSerie" => "Curr Allergy Asthma Rep&#46;"
                        "fecha" => "2018"
                        "volumen" => "18"
                        "paginaInicial" => "33"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29744661"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The international EAACI&#47;GA<span class="elsevierStyleSup">2</span>LEN&#47;EuroGuiDerm&#47;APAAACI guideline for the definition&#44; classification&#44; diagnosis&#44; and management of urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Zuberbier"
                            1 => "A&#46;H&#46;A&#46; Latiff"
                            2 => "M&#46; Abuzakouk"
                            3 => "S&#46; Aquilina"
                            4 => "R&#46; Asero"
                            5 => "D&#46; Baker"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/all.15090"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy&#46;"
                        "fecha" => "2022"
                        "volumen" => "77"
                        "paginaInicial" => "734"
                        "paginaFinal" => "766"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34536239"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab for the treatment of chronic spontaneous urticaria&#58; a meta&#8208;analysis of randomized clinical trials"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Z&#46;-T&#46; Zhao"
                            1 => "C&#46;-M&#46; Ji"
                            2 => "W&#46;-J&#46; Yu"
                            3 => "L&#46; Meng"
                            4 => "T&#46; Hawro"
                            5 => "J&#46;F&#46; Wei"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaci.2015.12.1342"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol"
                        "fecha" => "2016"
                        "volumen" => "137"
                        "paginaInicial" => "1742"
                        "paginaFinal" => "1750"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27040372"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic&#47;spontaneous urticaria&#58; a systematic review of &#8216;real&#8208;world&#8217;evidence"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;A&#46; Bernstein"
                            1 => "A&#46; Kavati"
                            2 => "M&#46;D&#46; Tharp"
                            3 => "B&#46; Ortiz"
                            4 => "K&#46; MacDonald"
                            5 => "K&#46; Denhaerynck"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Expert Opin Biol Ther&#46;"
                        "fecha" => "2018"
                        "volumen" => "18"
                        "paginaInicial" => "425"
                        "paginaFinal" => "448"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria&#58; evaluation of 154 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46;N&#46; Ghazanfar"
                            1 => "C&#46; Sand"
                            2 => "S&#46;F&#46; Thomsen"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "The British journal of dermatology&#46;"
                        "fecha" => "2016"
                        "volumen" => "175"
                        "paginaInicial" => "404"
                        "paginaFinal" => "406"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab for severe chronic spontaneous urticaria&#58; real&#8208;life experiences of 280 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Z&#46; Vadasz"
                            1 => "Y&#46; Tal"
                            2 => "M&#46; Rotem"
                            3 => "V&#46; Shichter-Confino"
                            4 => "K&#46; Mahlab-Guri"
                            5 => "Y&#46; Graif"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2017.08.035"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2017"
                        "volumen" => "5"
                        "paginaInicial" => "1743"
                        "paginaFinal" => "1745"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28988786"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab chronic spontaneous urticaria&#58; efficacy&#44; safety&#44; predictors of treatment outcome&#44; and time to response"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Nettis"
                            1 => "L&#46; Cegolon"
                            2 => "E&#46; Di Leo"
                            3 => "F&#46;L&#46; Rizzini"
                            4 => "A&#46; Detoraki"
                            5 => "G&#46;W&#46; Canonica"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anai.2018.06.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Allergy Asthma Immunol&#46;"
                        "fecha" => "2018"
                        "volumen" => "121"
                        "paginaInicial" => "474"
                        "paginaFinal" => "478"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29949781"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab is an effective and rapidly acting therapy in difficult&#8208;to&#8208;treat chronic urticaria&#58; a retrospective clinical analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46; Metz"
                            1 => "T&#46; Ohanyan"
                            2 => "M&#46;K&#46; Church"
                            3 => "M&#46; Maurer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Dermatol Sci&#46;"
                        "fecha" => "2014"
                        "volumen" => "73"
                        "paginaInicial" => "57"
                        "paginaFinal" => "62"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "K&#46; Kulthanan"
                            1 => "P&#46; Tuchinda"
                            2 => "L&#46; Chularojanamontri"
                            3 => "C&#46; Likitwattananurak"
                            4 => "C&#46; Ungaksornpairote"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/09546634.2016.1200710"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Dermatolog Treat&#46;"
                        "fecha" => "2017"
                        "volumen" => "28"
                        "paginaInicial" => "160"
                        "paginaFinal" => "165"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27388043"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "pt"
  "url" => "/26662752/0000009800000002/v1_202302281436/S2666275222003071/v1_202302281436/pt/main.assets"
  "Apartado" => array:4 [
    "identificador" => "95147"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Cartas - Investiga&#231;&#227;o"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/26662752/0000009800000002/v1_202302281436/S2666275222003071/v1_202302281436/pt/main.pdf?idApp=UINPBA00008Z&text.app=https://clinics.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222003071?idApp=UINPBA00008Z"
]
Informação do artigo
ISSN: 26662752
Idioma original: Português
Dados atualizados diariamente
Ano/Mês Html Pdf Total
2024 Novembro 22 7 29
2024 Outubro 149 73 222
2024 Setembro 240 83 323
2024 Agosto 211 119 330
2024 Julho 201 104 305
2024 Junho 198 90 288
2024 Maio 153 62 215
2024 Abril 149 88 237
2024 Março 143 57 200
2024 Fevereiro 149 82 231
2024 Janeiro 134 47 181
2023 Dezembro 102 65 167
2023 Novembro 156 86 242
2023 Outubro 196 77 273
2023 Setembro 114 74 188
2023 Agosto 93 43 136
2023 Julho 95 44 139
2023 Junho 97 32 129
2023 Maio 82 31 113
2023 Abril 59 36 95
2023 Março 85 79 164
2023 Fevereiro 38 46 84
2023 Janeiro 18 26 44
Mostrar tudo

Siga este link para acessar o texto completo do artigo

Idiomas
Anais Brasileiros de Dermatologia (Portuguese)
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.